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Abstract 
 
Cervical cancer is the fourth most common cancer affecting women worldwide but mortality can be 
decreased by early detection of pre-malignant lesions.  The Pap smear test is the most commonly used 
method in cervical cancer screening programmes. Although specificity is high for this test, it is widely 
acknowledged that sensitivity can be poor mainly due to the subjective nature of this test. There is a 
need for new objective tests for the early detection of pre-malignant cervical lesions. Over the past 
two decades, Raman spectroscopy has emerged as a promising new technology for cancer screening 
and diagnosis.  The aim of this study was to evaluate the potential of Raman spectroscopy for cervical 
cancer screening using both Cervical Intraepithelial Neoplasia (CIN) or Squamous Intraepithelial Lesion 
(SIL) classification terminology. ThinPrep® Pap samples were recruited from a cervical screening 
population. Raman spectra were recorded from single cell nuclei and subjected to multivariate 
statistical analysis. Normal and abnormal Thinprep samples were discriminated based on the 
biochemical fingerprint of the cells using Principal Component Analysis (PCA). Principal Component 
Analysis – Linear Discriminant Analysis (PCA-LDA) was employed to build classification models based 
on either CIN or SIL terminology. This study has shown that Raman spectroscopy can be successfully 
applied to the study of routine cervical cytology samples from a cervical screening programme and 
that use of CIN terminology resulted in improved sensitivity for high grade cases.  
 
  
Introduction 
Cervical cancer is the fourth most common cancer in women worldwide, accounting for an estimated 
528,000 new cases and 266,000 deaths in 2012.1 However, the mortality associated with cervical cancer 
can be significantly reduced if this disease is detected at the early stages of development or at the pre-
cancer stage, termed cervical intraepithelial neoplasia (CIN). Cervical cancer mainly affects younger 
women, about 60% of cases occurring in women under 50 years of age. Persistent infection with 
Human Papillomavirus (HPV) (such as high risk HPV types 16 and 18) is accepted as the major cause for 
the development of cervical pre-cancer and cancer.2 Other risk factors include smoking, 
immunosuppression, long term use of oral contraceptives and socioeconomic status.3 
Cervical cancers are usually preceded by a long phase of pre-invasive disease. This phase is 
characterised microscopically as a sequence of events progressing from cellular atypia to various 
grades of dysplasia or CIN before progression to invasive carcinoma. Introduced in 1968, CIN is the 
most common terminology for cervical histology. It is a three-tiered system, divided into grades 1, 2 
and 3, whereby CIN 1 corresponds to mild dysplasia, CIN 2 to moderate dysplasia, and CIN 3 
corresponds to both severe dysplasia and carcinoma in situ.4 In cytology, the British Society for Clinical 
Cytology (BSCC) reporting system for cervical cancer refers to different grades of dyskaryosis which 
relate to the three-tiered CIN terminology with CIN 1 corresponding to mild dyskaryosis, CIN 2 
corresponding to moderate dyskaryosis and CIN 3 to severe dyskaryosis. Since then, advances in HPV 
research and liquid based cytology led to the introduction of the Bethesda System in the United States 
of America.5 According to this nomenclature, squamous intraepithelial lesion (SIL) encompasses a 
range of non-invasive cervical epithelial abnormalities, comprising low grade (LSIL) and high grade 
lesions (HSIL).  Low grade lesions correspond to cellular changes associated with the HPV cytopathic 
effect (koilocytotic atypia) and mild dysplasia (CIN 1), whereas high grade lesions correspond to 
moderate dysplasia, severe dysplasia, and carcinoma in situ (CIN 2 and 3). The two-tiered terminology 
of SIL is the standard reporting system for cervical cytology used in many screening programmes 
across developed countries.  Since 2012, the College of American Pathologists and the American 
Society for Colposcopy and Cervical Pathology has recommended a uniform terminology to describe 
the histology of HPV-associated squamous disease across all anogenital sites. The two tiered 
terminology of LSIL and HSIL is recommended, as it reflects the biology of transient HPV infections and 
persistent precancerous lesions.6  More recently, the BSCC terminology was also revised to comprise 
the terms low grade, high grade with the option of high grade dyskaryosis being further reported as 
moderate or severe.7  Table 1 summarises the different classification systems. 
 
The gradual progression of cervical cancer can allow the detection of dysplastic changes before 
invasive cancer develops through cervical cancer screening programmes. These screening 
programmes are common in developed countries, greatly reducing the mortality rates due to cervical 
cancer, but are not yet implemented in developing countries due to lack of infrastructure and funding. 
The Papanicolaou (Pap) test is the most common screening method for cervical cancer and its 
precursor lesions.8 The advantages of the Pap test are that it is non-invasive, inexpensive and widely 
accepted. However, although it can have high specificity of up to 95-98%, sensitivity rates can vary 
from 74 to 96%, due to sampling, technical and/or interobserver errors which are associated with the 
subjective nature of cytological screening.9  There is, therefore, a need for new objective screening 
tests for cervical cancer. 
 
Over the past 15 years, excellent sensitivity and specificity values have been reported using vibrational 
spectroscopy, InfraRed (IR) and Raman, for the diagnosis of a wide range of cancers, including breast, 
prostate, oesophageal, colon, lung, oral and cervical cancer.10-12  IR spectroscopy is based on the 
absorption of infrared radiation by the sample and the fact that molecules absorb specific frequencies 
of the incident light which are characteristic of their structure. Raman spectroscopy is an optical method 
based on inelastic light scattering. The sample is illuminated by monochromatic laser light and 
interactions between the incident photons and molecules in the sample result in scattering of the 
light. The coupling of the light generates vibrations within the material which are characteristic of the 
chemical structure and the energy of the scattered light is reduced by an amount equal to the energy 
of the vibrational energy. Thus, the positions, relative intensities and shapes of the bands in a Raman 
spectrum carry detailed information about the molecular composition of the sample.  
A number of papers by Wong and co-workers in the early 1990’s showed significant differences in 
cervical cytology cells between normal, pre-cancer and cancer samples using IR spectroscopy.13-16  
However, these initial studies recorded spectra from cell pellets rather than from individual cells and a 
number of confounding factors such as neutrophils, endocervical columnar cells, metaplastic cells, 
cervical mucus and debris were subsequently identified.17 Similar confounding factors, such as 
inflammation, metaplasia, hormonal changes, metabolic activity, blood and mucus, were identified by 
other groups.18-22 Nevertheless, an early study by Cohenford and Rigas23 reported an important finding 
that morphologically normal exfoliated cells from women with dysplasia or cancer exhibited extensive 
IR spectral changes. This finding was confirmed by Schubert et al.24, who showed spectral changes in 
cytologically normal cells in dysplastic samples, most likely due to HPV infection. Significant overlap 
was observed between negative, LSIL and HSIL cases using ATR—FTIR spectroscopy with maximal 
overlap between negative and LSIL cases25. but a more recent study showed that cervical pre-cancer 
is more accurately identified when histology rather than cytology is used as the gold standard to 
classify the samples.26 
There are relatively fewer studies on cervical cytology using Raman spectroscopy, most likely because 
of the issues with confounding factors.  Vargis et al.27 showed that Raman spectroscopy could classify 
HPV-positive and HPV-negative cytology samples with an accuracy of 98.5%. Rubina  et al.28 reported a 
classification accuracy of ~80% using Raman spectroscopy to distinguish between normal and cervical 
cancer cytology samples. Cytology samples were treated with red blood cell lysis buffer prior to Raman 
acquisition as the spectra of cervical cancer samples were dominated by blood features. Both of these 
studies used cell pellets rather than recording Raman spectra from individual cells and this probably 
resulted in the relatively low classification accuracy in the study by Rubina et al. due to sample 
heterogeneity. A recent study by Bonnier et al.29 presented new methods for recording Raman spectra 
from ThinPrep cervical cytology samples. Pre-treatment of the slides with hydrogen peroxide to clear 
blood residue contamination before Raman recording was shown to minimise variability within the 
data sets resulting in the collection of highly reproducible data with clear discrimination between 
negative cytology and CIN cytology. All data was recorded on glass ThinPrep slides which are currently 
used for clinical cervical cytology rather than spectroscopic substrates such as calcium fluoride 
substrates which are commonly used in biospectroscopy research studies. Although these substrates 
reduce the presence of confounding contributions of the substrate, they are significantly more 
expensive which may prohibit clinical applications.30 
The aim of this study was to evaluate the potential of Raman spectroscopy for cervical cancer 
screening using routine cervical cytology samples from a cervical screening programme.  Cytology 
samples were classified according to both CIN and SIL terminology and Raman classification models 
compared. 
  
Experimental 
Sample Collection and slide preparation  
166 unstained smear samples in ThinPrepTM slides were obtained from the Western Health & Social 
Care Trust Altnagelvin Hospital, Northern Ireland, with the approval of the Research Ethics Committee 
Northern Ireland.  
Smears were collected, processed via the ThinPrepTM method, Papanicolau (Pap) stained and screened 
in the hospital by specialised personnel according to the guidelines in practice. A total of 88 negative, 
35 CIN1 (or 35 LSIL) and 21 CIN2 and 22 CIN3 (or 43 HSIL) cases were randomly selected and included 
in this study.  Each case represents a sample from an individual patient. 
One duplicate slide of each selected case was prepared using the ThinPrepTM method, fixed in 100% 
ethanol and air-dried. The samples were sent to Dublin Institute of Technology for Raman analysis.  
Before recording, each slide was pre-treated with hydrogen peroxidase (H2O2), as per an in-house 
protocol29 to remove any contaminating blood and debris. 
 
Raman Microspectroscopy  
Raman measurements were performed using a HORIBA Jobin Yvon XploRATM system (Villeneuve 
d’Ascq, France), which incorporates an Olympus microscope BX41 equipped with a x100 objective 
(MPlanN, Olympus, N.A. 0.9) and a 532nm diode laser source. To avoid any photo damage to the 
sample, the power of the laser was set at 50%. The confocal hole was set at 100µm and the 1200 
lines/mm grating was used, which gave a spectral dispersion of ~3 cm-1 per pixel. The backscattered 
light was collected using an air-cooled CCD detector (Andor, 1024 x 256 pixels) and the spectrometer 
was controlled by Labspec V5.0 software. The system was calibrated to the 520.7 cm-1 spectral line of 
silicon.  
Raman signals from each cell nucleus were integrated twice for 30 seconds in the spectral range of 
400-1800cm-1. Spectra from a minimum of 10 cell nuclei were recorded per sample, depending on 
the quality of each slide.  The data is presented as the average of all 10 cellular spectra recorded 
from each individual patient. 
 
 
Data analysis 
Data analysis was performed in Matlab [Mathworks, CA, USA] according to protocols developed in 
house.31 Pre-processing of the raw Raman spectra included the application of a Savitsky-Golay filter 
(5th order, 13 points) to smooth the spectra and the subtraction of the glass background according to 
an in house non-negative least squares (NNLS) model.32 The data set has also been corrected for 
baseline and vector normalized to facilitate comparison before principal component analysis (PCA) 
was employed to highlight the variability existing in the spectral data set recorded. Principal 
component analysis – linear discriminant analysis (PCA-LDA) was also employed to generate a 
classification model based on the features highlighted by PCA analysis. The optimal number of 
principal components (PCs) to generate the PCA-LDA model was established and 10 fold cross-
validation used to test it.  Furthermore, leave one out cross validation (LOOCV) was then used to 
evaluate the performance of the PCA-LDA classification model and sensitivity and specificity rates 
were calculated for both SIL and CIN classifications.  
 
  
Results 
Mean Raman spectra of cervical cytology samples in the fingerprint region of 400-1800 cm-1 are shown 
in figure 1a. The samples are presented according to the SIL classification system; negative, LSIL and 
HSIL. The main peaks are indicated and assignments are listed in table 1.33 The mean spectra of 
negative, LSIL and HSIL samples show similar features, the main differences being observed around 
the 1318/1339 cm-1 region, in which the ratio of the intensities of these two peaks increases from 
negative to LSIL and HSIL samples as shown in figure 1b. 
To further highlight any differences between the spectral profiles of the samples, PCA was employed. 
Figure 2a shows the PCA scatterplot for all SIL classified samples. From the PCA scatterplot, it can be 
seen that negative (green), LSIL (magenta) and HSIL (black) samples are separated according to the 
first (PC1) and second (PC2) principal components which account respectively for 76.81 % and 7.548 
% of the variance explained in the dataset. The loadings for PC1 and PC2 are shown in figure 2b and c.  
The negative samples seem to separate from the LSIL samples according to PC1, negative samples 
having more DNA (~814 cm-1), protein and lipids (1307, 1446, 1453 cm-1), Amide III (1242 cm-1) and I 
(1690 cm-1) also featuring prominently. Furthermore, the negative samples separate to a large extent 
from the HSIL samples according to PC2. Negative samples show stronger Amide III (1243, 1375 cm-1) 
and protein/lipid (1339 cm-1) features, whereas HSIL samples display stronger Amide I (1606 cm-1) and 
Amide II (1544 cm-1). In addition, the PC2 loading also highlights differences in nucleic acids, the 
features at 1458 and 1485/7 cm-1 being more prominent in the spectra of negative samples. DNA 
features at 481 and 786 cm-1 are more prominent in negative samples, whereas the feature at 893 cm-
1 is more prominent in HSIL samples. Similarly, phosphate and phosphodiester bonds at 812 cm-1 are 
more prominent in HSIL samples, whereas those at 1087-9 cm-1 are more prominent in negative 
samples. The separation between LSIL and HSIL samples results from a combination of PC1 and PC2. 
Taking the PC1 and PC2 assignments for the negative samples as a reference, the LSIL samples have a 
similar PC2 profile to the negative samples whereas the HSIL samples have a similar PC1 profile to the 
negative samples.  
The PCA results suggest that significant differences can be found in the Raman spectral profile of cell 
nuclei to distinguish between negative, LSIL and HSIL samples. PCA-LDA was therefore used to 
generate a classification model based on the features highlighted by PCA analysis.Results showed that 
a model with 12 PCs was best for LDA. Leave one out cross validation (LOOCV) was then used to 
evaluate the performance of the PCA-LDA classification model and sensitivity and specificity rates are 
shown in  table 3.  
Apart from the HSIL sensitivity, the performance of the PCA-LDA model is quite encouraging, all 
sensitivity and specificity values being above 90%. Sensitivity is also called the true positive fraction 
and accounts for the number of reported positives that are correctly identified as such. As the HSIL 
group consists of samples previously classed by the CIN classification system as CIN 2 and CIN 3, it was 
decided to re-evaluate the data according to the CIN classification.  
Figure 3a shows the mean Raman spectra of CIN 2 and CIN 3 samples. Only small differences can be 
observed; a peak at 1246 cm-1 assigned to Amide III and one at 1417 cm-1 assigned to C=C stretching 
in a quinoid ring are only observed in CIN 2 spectra whereas the CH3/CH2 twisting or bending mode of 
lipid/collagen at 1309 cm-1 is only evident in CIN 3 spectra.  
PCA was performed on the dataset according to the CIN classification and the PCA scatterplot is shown 
in figure 3b. CIN2 (red) is not clearly separated from the other sample groups but, along PC1, it can be 
seen distributed between CIN 3 (black) and CIN 1 (magenta) samples. To further elucidate the 
differences between all CIN samples, pairwise PCA was performed on spectra from CIN 1, CIN 2 and 
CIN 3 samples and the results are shown in figure 4.  CIN 1 and CIN 2 samples show some overlap but 
there is some separation along PC1 (figure 4a). PC1 is positively dominated by Amide I (1663 cm-1) and 
other protein features (~1309, 1449 cm-1), as shown in figure 4b, indicating that these are more 
prominent in CIN2 samples.  Similarly, CIN 1 and CIN 3 show some overlap but there is some separation 
along PC1 (figure 4c). In this case, PC1 is also positively dominated by Amide I (1669 cm-1) and other 
protein features (~1308, 1453 cm-1), as shown in figure 4d, indicating that these are more prominent 
in CIN 3 samples compared to CIN 1 samples.  CIN 2 and CIN 3 samples show reasonably good 
separation with some overlap along PC3 (figure 4e). PC3 is positively dominated by nucleic acid 
features at 722, 786, 810 and 850 cm-1 and Amide III at 1242 cm-1, which are more intense in the 
spectra of CIN 3 samples, whereas Amide I features at 1651 cm-1 and C-H vibration of proteins and 
lipids at 1449 cm-1 are more prominent in the Raman spectra of CIN 2 samples. 
For the PCA-LDA of the dataset according to the CIN classification, a model with 14 PCs was best for 
LDA and, similar to the SIL classification analysis, LOOCV was then used to evaluate the performance 
of the PCA-LDA classification model and sensitivity and specificity rates are shown in table 4.  All 
sensitivity and specificity values of the PCA-LDA model were greater than 90%. 
 
 
 
 
  
Discussion 
In this study Raman spectra were acquired from the nuclei of single cells of Thinprep cervical cytology 
specimens on glass slides. Recording spectra from the cell nuclei may explain the similarity between 
the average spectrum of the different sampling groups, as biochemically the nucleus of a normal cell 
and the nucleus of an abnormal cell are similar. Several studies have reported increases in nucleic 
acids in abnormal tissue samples compared to normal tissue samples.34-37 Abnormal tissue is 
characterised by increased cell proliferation rates and therefore more cells are expected to be 
detected/scanned (per area) on abnormal samples, resulting in substantial differences compared to 
normal tissue samples. In the present study, despite targeting the nuclei of the cells, it is mainly 
protein features which seem to discriminate the groups, although some differences in nucleic acid 
features were also observed. It should be noted that the Raman signals will have some degree of 
contribution from the cytoplasm of the cells as the laser passes through the cell to reach the nucleus. 
A previous study of cervical cytology specimens, although conducted on cellular pellets rather than 
cell monolayers, reported Amide I (1660 cm-1), ∂CH2 (1450 cm-1) and phenylalanine (1002 cm-1) as the 
main features dominating the Raman spectra of negative samples.28 After a treatment to remove 
blood from the samples an increase in protein content (at 1006, 1450 and 1660 cm-1) and changes in 
their secondary structure due to positive Amide III bands were found.  This adds to the case that 
instead of concentrating on increases and/or decreases in DNA and nucleic acids, Raman spectroscopy 
profiling for cervical cancer diagnosis can benefit from a better understanding of protein assignments.  
A change in ratio at 1318/1339 cm-1 was also observed for negative, LSIL and HSIL cases, suggesting a 
decrease in the lipid/protein to guanine ratio in LSIL and HSIL samples, which may result from either 
a reduction of lipids/proteins and/or an increase in the nucleic acid (guanine) content of these 
samples.  
 
The sensitivity and specificity values for the PCA-LDA models generated in this study were extremely 
high, especially when compared with Pap screening.9 All values in the CIN classification were greater 
than 90% and with the exception of the HSIL sensitivity of ~ 86%, the same was also observed for the 
SIL classification. The lower HSIL sensitivity value of 86% seems to suggest that the CIN 2 cases are 
from a heterogeneous group and perhaps some of the samples diagnosed as such might be 
biochemically closer to CIN 1 than CIN 3 and therefore may not be correctly classified as HSIL. 
In fact, a recent study by Doorbar et al.38 which investigated the correlation of CIN classification and 
HPV infection status suggested that some reported CIN 2 cases, when analysed by an 
immunohistochemistry panel of P16INK4a, MCM and HPV-encoded E4, in fact group with CIN 1 rather 
than CIN 3 cases. The study showed that the combination of identification of surrogates of high-risk 
HPV E6/E7 activity (P16INK4a and MCM), together with the detection of the abundant HPV-encoded 
E4 protein, was able to identify both transient and transforming lesions. This approach not only 
allowed to distinguish true papillomavirus infections from similar pathologies but also to divide the 
heterogeneous CIN 2 category into those that are CIN 1-like with transient HPV infection expressing 
E4, and those that do not express E4 and therefore are more closely related to CIN 3 cases with 
transforming HPV infection. 
 
Conclusions 
This study has shown that Raman spectroscopy can be successfully applied to the study of Thinprep 
cervical cytology samples from a cervical screening programme.  Samples were prepared according to 
standard protocols and good quality Raman spectra were recorded from unstained single cervical cells 
on glass slides. Excellent sensitivity and specificity values were obtained particularly when CIN rather 
than SIL terminology was used to classify the samples.  This suggests that the HSIL category is quite 
heterogeneous with CIN2 cases being biochemically different to CIN3 cases.   
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Figure Legends 
Figure 1 a) Mean Raman spectra from negative, LSIL and HSIL cervical cytology samples. Shading 
denotes the standard deviation, b) 1318/1339 cm-1 peak ratios for negative, LSIL and HSIL cervical 
cytology samples. 
 
Figure 2 a) PCA scatterplot, b) PC1 loading and c) PC2 loading of negative, LSIL and HSIL cervical 
cytology samples. 
 
Figure 3 a) Mean Raman spectra from CIN 2 and CIN 3 cervical cytology samples. Shading denotes 
the standard deviation, b) PCA scatterplot for negative, CIN 1, CIN 2 and CIN 3 cervical cytology 
samples. 
 
Figure 4 a) PCA scatterplot and b) PC1 loading for CIN 1 and CIN 2 cervical cytology samples, c) PCA 
scatterplot and d) PC1 loading for CIN 1 and CIN 3 cervical cytology samples, e) PCA scatterplot and 
f) PC3 loading for CIN 2 and CIN 3 cervical cytology samples. 
 
 
 
  
Table 1 Summary of the different cervical cytology / histology reporting systems 
Cervical cytology / histology reporting systems 
CIN1  BSCC2 (1996) 
SIL3 (Bethesda) / 
CAP4 / ASCCP5 
 BSCC (2013) 
1 Mild dyskaryosis LSIL6 Low grade dyskaryosis 
2 Moderate dyskaryosis 
HSIL7 
High grade dyskaryosis  
(moderate) 
3 Severe dyskaryosis High grade dyskaryosis (severe) 
 
1 Cervical intraepithelial neoplasia; 2 British Society for Clinical Cytology; 3 Squamous intraepithelial lesion;          
4 College of American Pathologists; 5 American Society for Colposcopy and Cervical Pathology; 6 Low grade 
squamous intraepithelial lesion; 7 High grade squamous intraepithelial lesion 
 
  
Table 2  Tentative peak assignments28 for Raman spectra shown in Figure 1. 
Raman shift (cm-1) Assignment 
621 C-C twisting mode of phenylalanine (proteins) 
645 C-C twisting mode of phenylalanine (proteins) 
722 Adenine 
786 DNA: O-P-O; Pyrimidine ring breathing mode 
828 Phosphodiester; O-P-O stretching DNA/RNA 
856 Amino acid side chain vibrations of proline & 
Hydroxyproline, as well as a (C-C) vibration of the 
collagen backbone 
1032 CH2CH3 bending modes of collagen & phospholipids; 
Phenylalanine of collagen; Proline (collagen assignment) 
1093 Symmetric PO2- stretching vibration of the DNA 
backbone–phosphate backbone vibration as a marker 
mode for the DNA concentration C-N of proteins 
1127 ѵ(C-N) 
1175/76 Cytosine, guanine 
1209 Tryptophan & phenylalanine 
1240 Amide III; Differences in collagen content; Asymmetric 
phosphate stretching modes 
1246 Amide III (of collagen) 
1307 CH3/CH2 twisting, wagging &/or bending mode 
of collagens & lipids 
1318 Guanine (ring breathing modes of the DNA/RNA bases)-
C-H deformation (protein); Amide III (α-helix) 
1339 CH2/CH3 wagging & twisting mode in collagen, nucleic 
acid & tryptophan 
1451 CH2CH3 deformation 
1580 C-C stretching 
1607 C=C phenylalanine, tyrosine 
1617 C=C phenylalanine, tyrosine 
1670 Amide I; C=C stretching vibrations; Amide I (anti-parallel 
β-sheet); n(C=C) trans, lipids, fatty acids 
 
  
Table 3  Sensitivity and Specificity from Principal Component Analysis – Linear Discriminant Analysis 
(PCA-LDA) Classification of negative, LSIL and HSIL cervical cytology samples 
 
SIL classification 
Negative LSIL HSIL 
Sensitivity 100.00% 94.29% 86.05% 
Specificity 97.22% 95.42% 100.00% 
 
  
Table 4 Sensitivity and Specificity from Principal Component Analysis – Linear Discriminant Analysis 
(PCA-LDA) Classification of negative, CIN1, CIN2 and CIN3 cervical cytology samples 
 
CIN classification 
Negative CIN 1 CIN 2 CIN 3 
Sensitivity 100.00% 94.29% 100.00% 90.91% 
Specificity 97.37% 98.47% 97.24% 100.00% 
 
 
